Healthcare Services
U.S. Assisted Reproductive Technology (ART) Market

U.S. Assisted Reproductive Technology (ART) Market Size, Share, Growth, and Regional Forecast, 2026 to 2033

U.S. Assisted Reproductive Technology (ART) Market by Technique (In vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), Frozen Embryo Transfer (FET), Intrauterine Insemination (IUI)), By Procedure (Fresh Donor, Fresh non-Donor, Frozen Donor, Frozen non-Donor), End-user (Fertility Clinics, Hospitals, Research Centers), and Regional Analysis from 2026 to 2033

ID: PMRREP34680

January 2026

220 Pages

Author : Vaishnavi Patil

Healthcare

Key Industry Highlights:

Dominant Technique: In vitro fertilization (IVF) remains the most widely adopted ART procedure, followed by ICSI, cryopreservation, and GIFT/ZIFT procedures.
Fastest-Growing Technique: Frozen Embryo Transfer (FET) is anticipated to be an emerging technique in the U.S. due to higher success rates, safer protocols, improved cryopreservation, patient preference, and expanded clinic adoption.
Dominant Procedure: Frozen non-donor embryo transfers lead U.S. ART, driven by cryopreservation advances, safety, flexibility, genetic testing, convenience, and improved outcomes
Leading End-user: Fertility centers remain the core hubs of ART innovation and patient care in the U.S. ART market, owing to specialized expertise, advanced technology, personalized care, and superior success rates, while expanding access nationwide. Hospitals and research institutes play supportive roles, but fertility centers.
Recent innovations in assisted reproductive technology, including time-lapse embryo imaging, AI-driven embryo selection, advanced sperm sorting, and improved cryopreservation methods, have significantly enhanced success rates and patient outcomes in the U.S.

Key Insights	Details
U.S.Assisted Reproductive Technology Market Size (2026E)	US$10.5 Bn
Market Value Forecast (2033F)	US$14.8 Bn
Projected Growth (CAGR 2026 to 2033)	5.1%
Historical Market Growth (CAGR 2020 to 2025)	4.4%

Get Your CustomizationGet Your Customization

Market Dynamics

Driver - Rising Infertility Rate alongside Growing Adoption of Elective Egg Freezing

The U.S. assistive reproductive technology market is expanding rapidly due to rising infertility rates and technological breakthroughs. With nearly 270,000 IVF cycles annually, and ICSI used in 60-70% of them, patients are increasingly confident in ART as a reliable pathway to parenthood. The U.S. assisted reproductive technology (ART) market is being reshaped by a combination of cultural, clinical, and technological forces, with elective procedures such as egg freezing standing out as a major catalyst. Increasing numbers of women are choosing to delay parenthood in favor of career advancement, financial stability, or personal priorities, and egg freezing provides a practical solution to preserve fertility potential. This trend reflects broader cultural acceptance of non-traditional family planning timelines and highlights how reproductive choices are evolving in modern society. Changes in demographics and health have thus created a steady pipeline of patients seeking medical interventions to conceive.

Restraints - Rising Demand Fuels Ethical Concerns Amid Donor Sperm Shortage

The U.S. assisted reproductive technology market faces constraints owing to ethical debates around embryo selection, genetic testing, and cryopreservation, which adds regulatory scrutiny, slowing the adoption of newer technologies. Demand for donor eggs and sperm has risen sharply due to delayed parenthood, higher infertility rates, and increased use of assisted reproductive technologies like IVF and ICSI. However, supply has not kept pace. Egg donation requires invasive medical procedures, discouraging many potential donors, while sperm donation faces declining participation among younger men due to privacy concerns and stricter screening regulations. Uneven access to the treatment is another hurdle, with advanced labs and AI-driven embryo selection concentrated in large urban fertility networks, leaving rural patients underserved. Additionally, the physical and emotional burden of repeated cycles discourages continuation; nearly 30% of patients discontinue after one failed attempt, thereby limiting overall market growth.

Opportunity - Oncofertility programs to offer cancer patients proactive fertility solutions

Oncofertility preservation programs in the U.S. are expanding to support cancer patients facing fertility risks from treatment. According to the American Society of Clinical Oncology (ASCO) each year, about 90,000 adolescents and young adults (ages 15-39) are diagnosed with cancer, yet only half are informed about fertility preservation options. Several leading medical centers offer oncofertility preservation programs that integrate reproductive technologies such as egg and embryo freezing, sperm banking, and ovarian tissue preservation to help cancer patients safeguard their fertility before treatment. These programs are expanding nationwide, supported by collaborations between oncology and reproductive specialists. Centers such as MD Anderson, UCSF, and UConn’s Center for Advanced Reproductive Services are leading examples, offering integrated care, advanced cryopreservation, and genetic testing to secure reproductive futures for oncology patients.

Recent initiatives highlight the importance of patient education, as studies show that less than 50% of young cancer patients are informed about fertility risks before treatment. Advocacy groups and oncology societies are pushing for standardized fertility counseling across all cancer centers. With survival rates improving, the demand for fertility preservation in the U.S. continues to grow, ensuring that cancer survivors retain the possibility of parenthood and long-term quality of life.

Category-wise Analysis

By Technique, In vitro Fertilization remains the foundational ART procedure, followed by ICSI

In the U.S., IVF leads the assisted reproductive technology (ART) market because it is the most widely adopted procedure, generating the highest revenue and offering broad applicability across infertility cases. Rising infertility rates, delayed parenthood, and technological advances make IVF the cornerstone of ART services nationwide. Availability of add-on services that enhance success rates and increase overall treatment value further boosts the demand for IVF. Add-on procedures such as preimplantation genetic testing (PGT) allow clinicians to screen embryos for chromosomal abnormalities, improving implantation outcomes and reducing miscarriage risks. Similarly, cryopreservation techniques enable patients to store embryos for future use.

Intracytoplasmic Sperm Injection (ICSI) follows the IVF procedures as it directly addresses male-factor infertility, which accounts for a significant portion of ART cases nationwide. By injecting a single healthy sperm into the egg, ICSI ensures higher fertilization rates even when sperm count, motility, or morphology is compromised. Beyond male infertility, clinics employ ICSI for couples with prior IVF failures, diminished ovarian reserve, advanced maternal age, or unexplained infertility, making it broadly applicable and widely adopted.

By End-user, Fertility Clinics are Leading

Fertility clinics in the U.S. hold the largest market share because they are highly specialized centers focused exclusively on reproductive care, unlike general hospitals, which balance multiple medical priorities. These clinics deliver comprehensive, end-to-end services ranging from diagnostics and IVF stimulation cycles to embryology labs, genetic testing, counseling, and cryopreservation, all within a single integrated setup, which drives higher patient volumes. Their infrastructure is tailored specifically to IVF workflows, enabling precise cycle monitoring, faster turnaround times, and more personalized clinical attention. U.S. fertility clinics also invest significantly in advanced embryology technologies, incubators, culture media, and digital tracking systems, which contribute to stronger perceived success rates. Since most infertility treatments in the U.S. are elective, privately financed, and time-sensitive, patients tend to favor clinics that offer confidentiality, flexible scheduling, and transparent pricing models. Moreover, the rapid growth of private IVF networks across the country has further cemented the dominance of specialized fertility clinics in the American assisted reproductive technology market.

Request Free sampleRequest Free sample

Regional Insights

Northeast U.S. Assisted Reproductive Technology Market Trends

The Northeast leads the U.S. in assisted reproductive technologies because of its unique mix of strong insurance mandates, dense networks of fertility clinics, and world-class medical research institutions. The Northeast’s combination of policy support, medical infrastructure, and patient demand makes it the dominant region in shaping national trends in fertility care. In states such as Massachusetts and New York, access to infertility treatment is significantly greater than in many other parts of the U.S. Massachusetts is frequently regarded as the benchmark, thanks to its extensive insurance mandate that requires coverage for IVF and related procedures. This policy substantially lowers the financial barriers for patients, encouraging wider use of assisted reproductive technologies. Similarly, New York has expanded its insurance coverage, making treatments such as IVF, ICSI, FET, and IUI more accessible to a larger share of residents without incurring excessive costs.

Beyond insurance, the Northeast is home to prestigious academic medical centers such as Harvard-affiliated hospitals in Boston and major research hubs in New York City. These institutions not only provide state-of-the-art clinical care but also drive innovation in reproductive medicine, from advanced embryo-freezing techniques to genetic screening. The region’s high population density further supports many specialized fertility clinics, creating competition that fosters quality improvements and higher success rates.

Southeast U.S. Assisted Reproductive Technology Market Trends

The assisted reproductive technology (ART) sector in the Southeast U.S. is experiencing significant expansion, with in vitro fertilization (IVF) remaining the leading treatment option. Fertility centers in states such as Florida and Georgia are increasingly incorporating preimplantation genetic testing (PGT) to enhance pregnancy outcomes and lower the likelihood of miscarriages. Elective egg freezing is increasingly prevalent across the Southeastern U.S., reflecting shifting cultural values and career-focused lifestyles. Women in cities like Atlanta and Miami are choosing fertility preservation to balance professional ambitions with family planning. This trend underscores broader acceptance of delayed parenthood and growing demand for advanced reproductive options.

Male infertility solutions, particularly intracytoplasmic sperm injection (ICSI), are becoming increasingly common in fertility clinics across North Carolina and Tennessee. This technique, which involves injecting a single sperm directly into an egg, is helping couples overcome severe male-factor infertility and achieve higher success rates. The growing demand reflects both improved awareness and the availability of advanced reproductive technologies in the region. Patients from other U.S. regions, including the Northeast and West Coast, travel to Florida clinics due to lower treatment costs, bundled service packages, and shorter wait times. Florida’s reputation for providing high-quality care at lower costs has positioned it as a destination for couples seeking accessible ART options. This trend is further supported by the presence of internationally recognised fertility centres in cities such as Miami and Jacksonville, which attract patients not only from across the U.S. but also from Latin America and the Caribbean.

Competitive Landscape

Success in the U.S. assistive reproductive technology market depends on balancing innovation with patient-centered care, expanding reach through networks and collaborations, and maintaining competitive pricing models that make advanced reproductive solutions more accessible to a wider population. The competition is also shaped by geographic expansion and the creation of extensive clinic networks that improve accessibility for patients across diverse regions. Many providers emphasize integrated, patient-centric services, combining medical expertise with counseling, wellness programs, and digital platforms to create a holistic treatment experience. Pricing strategies and customized treatment packages are increasingly used to attract patients, offering flexibility and affordability in what is often a high-cost medical journey. Partnerships with hospitals, universities, and research institutions further differentiate providers, enabling them to leverage cutting-edge science and broaden their referral base.

Key Industry Developments:

In October 2025, Overture Life announced the opening of its Dallas facility. The site offers non-invasive, CLIA-licensed embryo-assessment testing that analyzes molecules in the fluid surrounding embryos (metabolomics) with machine-learning support, providing fertility teams with objective data to inform embryo selection without a biopsy.
In September 2025, Conceivable Life Sciences secured $50 million in Series A funding led by Advance Venture Partners to accelerate development of its AI-powered automated IVF laboratory platform with advanced robotic precision. Existing investors ARTIS Ventures, Stride, and ACME participated in the round, bringing total funding to $70 million.
In August 2025, a US-based reproductive health biotech firm secured US$44 million in Series C funding led by Overwater Ventures, raising its total investment to US$127 million.
In April 2025, IVI RMA North America partnered with TMRW Life Sciences to digitize the management and storage of IVF Specimens across all clinics. TMRW will safely store the eggs and embryos of tens of thousands of IVI RMA North America patients, both onsite across its 22+ IVF labs and offsite at TMRW’s state-of-the-art biorepositories.

Companies Covered in U.S. Assisted Reproductive Technology (ART) Market

The Fertility Institutes
Shady Grove Fertility
Pacific Fertility Centre
Boston IVF
Cleveland Clinic Fertility Centre
Reproductive Medicine Associates of New Jersey (RMANJ)
Columbia University Fertility Centre
Mayo Clinic Fertility Centre
Texas Fertility Centre
UCSF Centre for Reproductive Health
Bloom IVF Centre
California Cryobank
Others

Frequently Asked Questions

The U.S. assisted reproductive technology market is projected to be valued at US$10.5 Bn in 2026.

Increasing infertility among couples due to delayed parenthood, lifestyle changes, stress, pollution, and medical conditions fuels demand for ART treatments.

The U.S. assisted reproductive technology market is poised to witness a CAGR of 5.1% between 2026 and 2033.

Adoption of AI-assisted embryo selection, lab automation, and digital monitoring can improve success rates and operational efficiency.

Northeast region of the U.S. is the leading zone in the U.S. Assisted Reproductive Technology Market.

Report Attribute	Details
Historical Data/Actuals	2020 - 2025
Forecast Period	2026 - 2033
Market Analysis	Value: US$ Bn; Volume: Units (If applicable)
Geographical Coverage	Northeast Southeast Midwest Southwest West
Segmental Coverage	By Technique By Procedure By End-user By Zone
Competitive Analysis	The Fertility Institutes Shady Grove Fertility Pacific Fertility Centre Boston IVF Cleveland Clinic Fertility Centre Reproductive Medicine Associates of New Jersey (RMANJ) Columbia University Fertility Centre Mayo Clinic Fertility Centre Texas Fertility Centre UCSF Centre for Reproductive Health Bloom IVF Centre California Cryobank Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets Market Analysis Tools

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Key Insights

Details

U.S.Assisted Reproductive Technology Market Size (2026E)

US$10.5 Bn

Market Value Forecast (2033F)

US$14.8 Bn

Projected Growth (CAGR 2026 to 2033)

5.1%

Historical Market Growth (CAGR 2020 to 2025)

4.4%

Report Attribute	Details
Historical Data/Actuals	2020 - 2025
Forecast Period	2026 - 2033
Market Analysis	Value: US$ Bn; Volume: Units (If applicable)
Geographical Coverage	Northeast Southeast Midwest Southwest West
Segmental Coverage	By Technique By Procedure By End-user By Zone
Competitive Analysis	The Fertility Institutes Shady Grove Fertility Pacific Fertility Centre Boston IVF Cleveland Clinic Fertility Centre Reproductive Medicine Associates of New Jersey (RMANJ) Columbia University Fertility Centre Mayo Clinic Fertility Centre Texas Fertility Centre UCSF Centre for Reproductive Health Bloom IVF Centre California Cryobank Others
Report Highlights	Market Forecast and Trends Competitive Intelligence & Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Future Opportunities and Revenue Pockets Market Analysis Tools

Executive Summary
1. U.S. Assisted Reproductive Technology Market Snapshot, 2026 and 2033
2. Market Opportunity Assessment, 2026 - 2033, US$ Bn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Challenges
  5. Key Trends
3. Macro-Economic Factors
  1. Global & U.S. Sectorial Outlook
  2. Global & U.S. GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. U.S. Infertility: Statistics, Trends, Causes & Risk Factors
2. Technique Adoption Analysis
3. Regulatory Landscape
4. Value Chain Analysis
5. Key Deals and Mergers
6. PESTLE Analysis
7. Porter’s Five Force Analysis
8. Impact of AI
U.S. Assisted Reproductive Technology Market Outlook:
1. Key Highlights
  1. Market Size (US$ Bn) and Y-o-Y Growth
  2. Absolute $ Opportunity
2. Market Size (US$ Bn) Analysis and Forecast
  1. Historical Market Size (US$ Bn) Analysis, 2020-2025
  2. Market Size (US$ Bn) Analysis and Forecast, 2026-2033
3. U.S. Assisted Reproductive Technology Market Outlook: Technique
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Technique, 2020 - 2025
  3. Market Size (US$ Bn) Analysis and Forecast, By Technique, 2026 - 2033
    1. In Vitro Fertilization (IVF)
    2. Intracytoplasmic Sperm Injection (ICSI)
    3. Frozen Embryo Transfer (FET)
    4. Intrauterine Insemination (IUI)
  4. Market Attractiveness Analysis: Technique
4. U.S. Assisted Reproductive Technology Market Outlook: Procedure
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Procedure, 2020 - 2025
  3. Market Size (US$ Bn) Analysis and Forecast, By Procedure, 2026 - 2033
    1. Fresh Donor
    2. Fresh non-Donor
    3. Frozen Donor
    4. Frozen non-Donor
  4. Market Attractiveness Analysis: Procedure
5. U.S. Assisted Reproductive Technology Market Outlook: End User
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By End User, 2020 - 2025
  3. Market Size (US$ Bn) Analysis and Forecast, By End User, 2026 - 2033
    1. Fertility Clinics
    2. Hospitals
    3. Research Centers
  4. Market Attractiveness Analysis: End User
U.S. Assisted Reproductive Technology Market Outlook: Zone
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Zone, 2020 - 2025
3. Market Size (US$ Bn) Analysis and Forecast, By Zone, 2026 - 2033
  1. Northeast
  2. Southeast
  3. Midwest
  4. Southwest
  5. West
4. Market Attractiveness Analysis: Region
Northeast U.S. Assisted Reproductive Technology Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 - 2025
  1. By Technique
  2. By Procedure
  3. By End User
3. Market Size (US$ Bn) Analysis and Forecast, By Technique, 2026 - 2033
  1. In Vitro Fertilization (IVF)
  2. Intracytoplasmic Sperm Injection (ICSI)
  3. Frozen Embryo Transfer (FET)
  4. Intrauterine Insemination (IUI)
4. Market Size (US$ Bn) Analysis and Forecast, By Procedure, 2026 - 2033
  1. Fresh Donor
  2. Fresh non-Donor
  3. Frozen Donor
  4. Frozen non-Donor
5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2026 - 2033
  1. Fertility Clinics
  2. Hospitals
  3. Research Centers
6. Market Attractiveness Analysis
Southeast U.S. Assisted Reproductive Technology Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 - 2025
  1. By Technique
  2. By Procedure
  3. By End User
3. Market Size (US$ Bn) Analysis and Forecast, By Technique, 2026 - 2033
  1. In Vitro Fertilization (IVF)
  2. Intracytoplasmic Sperm Injection (ICSI)
  3. Frozen Embryo Transfer (FET)
  4. Intrauterine Insemination (IUI)
4. Market Size (US$ Bn) Analysis and Forecast, By Procedure, 2026 - 2033
  1. Fresh Donor
  2. Fresh non-Donor
  3. Frozen Donor
  4. Frozen non-Donor
5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2026 - 2033
  1. Fertility Clinics
  2. Hospitals
  3. Research Centers
6. Market Attractiveness Analysis
Midwest U.S. Assisted Reproductive Technology Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 - 2025
  1. By Technique
  2. By Procedure
  3. By End User
3. Market Size (US$ Bn) Analysis and Forecast, By Technique, 2026 - 2033
  1. In Vitro Fertilization (IVF)
  2. Intracytoplasmic Sperm Injection (ICSI)
  3. Frozen Embryo Transfer (FET)
  4. Intrauterine Insemination (IUI)
4. Market Size (US$ Bn) Analysis and Forecast, By Procedure, 2026 - 2033
  1. Fresh Donor
  2. Fresh non-Donor
  3. Frozen Donor
  4. Frozen non-Donor
5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2026 - 2033
  1. Fertility Clinics
  2. Hospitals
  3. Research Centers
6. Market Attractiveness Analysis
Southwest U.S. Assisted Reproductive Technology Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 - 2025
  1. By Technique
  2. By Procedure
  3. By End User
3. Market Size (US$ Bn) Analysis and Forecast, By Technique, 2026 - 2033
  1. In Vitro Fertilization (IVF)
  2. Intracytoplasmic Sperm Injection (ICSI)
  3. Frozen Embryo Transfer (FET)
  4. Intrauterine Insemination (IUI)
4. Market Size (US$ Bn) Analysis and Forecast, By Procedure, 2026 - 2033
  1. Fresh Donor
  2. Fresh non-Donor
  3. Frozen Donor
  4. Frozen non-Donor
5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2026 - 2033
  1. Fertility Clinics
  2. Hospitals
  3. Research Centers
6. Market Attractiveness Analysis
West U.S. Assisted Reproductive Technology Market Outlook:
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2020 - 2025
  1. By Technique
  2. By Procedure
  3. By End User
3. Market Size (US$ Bn) Analysis and Forecast, By Technique, 2026 - 2033
  1. In Vitro Fertilization (IVF)
  2. Intracytoplasmic Sperm Injection (ICSI)
  3. Frozen Embryo Transfer (FET)
  4. Intrauterine Insemination (IUI)
4. Market Size (US$ Bn) Analysis and Forecast, By Procedure, 2026 - 2033
  1. Fresh Donor
  2. Fresh non-Donor
  3. Frozen Donor
  4. Frozen non-Donor
5. Market Size (US$ Bn) Analysis and Forecast, By End User, 2026 - 2033
  1. Fertility Clinics
  2. Hospitals
  3. Research Centers
6. Market Attractiveness Analysis
Competition Landscape
1. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. The Fertility Institutes
    1. Overview
    2. Segments and Products
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Shady Grove Fertility
  3. Pacific Fertility Centre
  4. Boston IVF
  5. Cleveland Clinic Fertility Centre
  6. Reproductive Medicine Associates of New Jersey (RMANJ)
  7. Columbia University Fertility Centre
  8. Mayo Clinic Fertility Centre
  9. Texas Fertility Centre
  10. UCSF Centre for Reproductive Health
  11. Bloom IVF Centre
  12. California Cryobank
  13. Others
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

U.S. Assisted Reproductive Technology (ART) Market Size, Share, Growth, and Regional Forecast, 2026 to 2033